Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)

Wendy Ha1, Hatice Sevim-Nalkiran2, Ashraf M. Zaman1, Kazuko Matsuda3, Mustafa Khasraw4, Anna K. Nowak5, Liping Chung6, Robert C. Baxter6 & Kerrie L. McDonald1

Recurrence in patients with glioblastoma (GBM) is inevitable resulting in short survival times, even in patients with O-6-Methylguanine-DNA Methyltransferase (MGMT) methylation. Other pathways must be activated to escape from temozolomide (TMZ) treatment, however acquired resistance mechanisms to TMZ are not well understood. Herein, frozen tumors from 36 MGMT methylated patients grouped according to overall survival were extracted and proteins were profiled using surface-enhanced laser desorption/ionization (SELDI) with time-of-flight (TOF) proteomics to identify low molecular weight proteins that associated with poor survival outcomes. Overexpression of macrophage migration inhibitory factor (MIF) was identified in human GBM specimens that were MGMT methylated but showed poor survival. This correlation was confirmed in an independent cohort of human GBM. MIF overexpression has been reported in several cancer types, including GBM. We repurposed ibudilast, a specific MIF inhibitor, and treated patient derived cell lines. Ibudilast showed modest anti-proliferative activity however, when combined with TMZ, significant synergism was observed, resulting in cell cycle arrest and apoptosis. In vivo, combined ibudilast and TMZ treatment of a patient derived xenograft (PDX) model resulted in significantly longer overall survival. Our findings have significant clinical implications for people with GBM. Since clinical trials involving ibudilast have shown no adverse side effects and the drug readily penetrates the blood brain barrier, treatment of GBM with this combination is clinically achievable.

Brain cancers affect people of all ages and are the most common cause of cancer death in children and young adults1. People with grade IV glioma (glioblastoma or GBM) face a poor prognosis and inevitable tumor recurrence. GBM has a median survival of less than 15 months2. The current optimal treatment for people with GBM who are fit consists of maximal safe surgical resection (gross total resection; GTR) then external beam irradiation with concomitant temozolomide (TMZ). This is followed by 6 months of TMZ therapy, which results in a 2.5-month improvement in survival over radiotherapy alone3.

Methylguanine-DNA methyltransferase (MGMT) removes mutagenic alkyl adducts, thereby protecting DNA from the damage induced by TMZ and other alkylating agents. Loss of MGMT expression is a frequent event in various human cancers4. MGMT expression in cells is regulated by hypermethylation of the CpG islands within the promoter and enhancer regions of the gene5-7. In tumors with a methylated MGMT promoter, MGMT deficiency is presumed, resulting in the enhanced effects of TMZ7.

Detection of MGMT promoter methylation correlates strongly with clinical response to TMZ and is also a positive prognostic biomarker in TMZ-treated GBM, including in elderly patients8,9. There has been considerable enthusiasm to use MGMT as a predictive biomarker for GBM patients, with the long-term scope for its use as a
Results
Identification and validation of MIF expression as a marker of poor prognosis. We selected 36 frozen newly diagnosed GBM specimens that were MGMT promoter methylated. Our reasoning behind selecting only methylated patients was that we wanted to see an initial response to TMZ. All patients had undergone maximal safe resection and were treated with concurrent RT and TMZ followed by adjuvant TMZ (Table 1). Sixteen patients were treated with salvage chemotherapies at progression including carboplatin, lomustine and bevacizumab. The median survival of the cohort selected was 13.8 months. The cohort was further categorized into two groups based on the median survival; Group 1: survival < 13.8 months (n = 18) and Group 2: survival ≥ 13.8 months (n = 18). Proteins were extracted and subjected to SELDI-TOF MS (Fig. 1A).

We found 39 peaks to be differentially expressed between the groups, with 7 identified peaks down-regulated and 32 peaks up-regulated in Group 1 (Fig. 1B). Peak clusters with high p-value, AUC and peak quality were subjected to backward stepwise BLR analysis in order to generate a reliable biomarker panel and to evaluate the combined discrimination power of the selected biomarker candidates. A panel of significantly up-regulated proteins in Group 1 (m/z 10247, 12361 and 10850 Da) was found to be the best model capable of distinguishing Group 1 from Group 2 tumors with 100% sensitivity and specificity (Fig. 1C). These three proteins were further purified for identification using ion-exchange separation and peptide matches were detected using liquid chromatography tandem mass spectrometry (LC-MS/MS). Mascot search reporting of the protein tryptic digests identified specific sequences of the 3 selected biomarkers (10.2, 12.3 and 10.8 kDa) to be alpha Defensin-3 (DEFA3), macrophage migration inhibitory factor (MIF) and calgranulin A (S100A8). Primary antibodies to the proteins confirmed the identity and overexpression in protein lysates from Group 1 and Group 2 patients (Fig. 1D). From the Western blot analysis, MIF expression was clearly distinguishable between Group 1 and Group 2 tumors and thus the remainder of our studies focused on MIF ROC curve analysis was performed for MIF as an individual biomarker. The predictive value of MIF was 0.882 with an asymptotic significance of >0.01, indicating good discriminating ability.

We assessed the protein expression of MIF in an independent cohort of 168 human GBM samples using IHC. The clinical features of patients from whom these samples were derived are summarized in Table 2. MIF staining was specific to the tumor cell membrane, as well as cytoplasm (Fig. 2A,B). One hundred and thirteen (67%) patients stained positive for MIF and was significantly associated with poor survival outcomes (Fig. 2C). MIF expression has been previously associated with poor prognosis and early tumor recurrence in GBM14–16. Patients whose tumors were negative for MIF showed a median survival time of 19 months compared to 11 months for MIF positive tumors (LogRank p < 0.0001). The hazard ratio was 2.4 (1.74–3.31) for patients with MIF positive expression.

|                | Group 1 (survival <13.8 months) | Group 2 (survival ≥13.8 months) | p-value |
|----------------|---------------------------------|---------------------------------|---------|
| Gender         |                                 |                                 |         |
| Male (%)       | 90                              | 80                              |         |
| Female (%)     | 10                              | 20                              |         |
| Age            |                                 |                                 |         |
| Median (years) | 66.9                            | 61.4                            | 0.025   |
| Range (years)  | 50–75                           | 31–83                           |         |
| XRT/TMZ (%)    | 100                             | 100                             |         |
| Treatment given at progression (%) | 33                        | 55                              | 0.0002  |
| MGMT methylation (%) | 100                    | 100                             |         |
| Survival       |                                 |                                 |         |
| Median (months) | 10.53                         | 20.83                           | 0.0023  |
| Range (months) | 2.5–13.4                       | 13.9–50.3                       |         |

Table 1. Clinical features of GBM patients enrolled in the proteomics analysis. Abbreviations: XRT/TMZ: Concurrent radiotherapy and temozolomide (TMZ) plus adjuvant temozolomide.
tumor tissue. For all 168 GBM specimens, MGMT promoter methylation status was known. The patients were categorized into 4 groups: MIF+ and MGMT methylated (n=55); MIF+ and MGMT unmethylated (n=58); MIF- and MGMT methylated (n=24); MIF- and MGMT unmethylated (n=17). MGMT methylation status was irrelevant in the MIF+ tumors (median survival 12 months versus 10 months for MGMT methylated and unmethylated tumors) (Fig. 2D). However, methylation of the MGMT promoter was strongly associated with better survival in the group of MIF- tumors (29 months versus 17 months) for MGMT methylated and

Table 2. Clinical Features of GBM patients enrolled in the immunohistochemistry analysis. Abbreviations: XRT/TMZ: Concurrent radiotherapy and temozolomide (TMZ) plus adjuvant temozolomide.

|                  | MIF−  | MIF+  | p-value |
|------------------|-------|-------|---------|
| Gender           |       |       |         |
| Male (%)         | 49    | 66    | 0.0002  |
| Female (%)       | 51    | 3     |         |
| Age              |       |       |         |
| Median (years)   | 56    | 59    | 0.059   |
| Range (years)    | 25–81 | 33–85 |         |
| MGMT             |       |       |         |
| Methylated (%)   | 54    | 50    | 0.010   |
| Unmethylated (%) | 46    | 50    |         |
| XRT/TMZ (%)      | 100   | 100   |         |
| Survival         |       |       |         |
| Median (months)  | 19.0  | 11.0  | <0.0001 |
| Range (months)   | 17.7–49.2 | 2.2–81.3 |         |
unmethylated tumors, respectively. This confirms our pilot study (Fig. 1) where we showed MIF+ve/MGMT methylated tumors were associated with poorer survival (Group 1 tumors).

Ibudilast treatment sensitizes GBM cells to temozolomide. To expedite rapid translation to the clinic, we performed a literature search to identify known pharmacological inhibitors of MIF. Ibudilast (MN166) is an orally available, small molecule drug and is a selective inhibitor of MIF17. Ibudilast distributes well to the CNS18 and inhibits MIF at clinically-relevant plasma or CNS concentrations. A panel of 8 patient derived cell lines (MGMT methylated: BAH1, G53, HW1 or MGMT unmethylated: RN1, G57, G89, G244) were tested with increasing concentrations of ibudilast (0–800 μM) and cell proliferation was measured with the MTS assay after 72-hours. The IC50 values ranged from 40–120 μM (data not shown).

Combining ibudilast with TMZ in vitro, proliferation was significantly inhibited in all cell lines compared to TMZ treatment alone (RN1 and BAH1 cells are shown in Fig. 3). Isobologram analysis using CompuSyn software determined that the enhanced effect of the combined treatment was synergistic for at least one of the fractional effect (Fa) doses demonstrated in the isobolograms and determined by the CI values (Table 3) for both cell lines.

We next examined combined ibudilast and TMZ treatment on cell cycle and apoptosis in vitro using the MGMT unmethylated cell line, RN1. Combined treatment significantly increased the effect on G1 cell cycle arrest compared with single agent ibudilast and vehicle treatments (Fig. 4A). Notably, combined treatment with ibudilast and TMZ significantly increased apoptosis as indicated by an increase in percentage of Annexin V+/propidium iodide− cells compared with single-agent and vehicle treatments (Fig. 4B). Western blot analysis confirmed the specificity of ibudilast on MIF, with expression significantly inhibited in the presence of the drug compared to vehicle-treated control cells (Fig. 4C; Supplementary Fig. 1). MIFs target receptor, CD74 was also inhibited in the presence of ibudilast. Combining ibudilast with TMZ reduced the levels of total and phosphorylated AKT and ERK (p44/42). Src physically associates with the intra-cytoplasmic domain of CD44, leading to phosphorylation, which then triggers downstream RAS/RAF/MEK/MAPK signaling. Increased Src expression was observed in the cells treated with the combination treatment. MIF-CD74 can complex with cysteine-X-cysteine (CXC) chemokine receptor, CXCR2. As can be seen in Fig. 4C, expression levels of CXCR2 were increased when exposed to ibudilast in combination with TMZ. Increased cleaved PARP, an indicator of apoptosis, increased with ibudilast and the combination treatment, consistent with that observed in Fig. 4B.

Ibudilast combined with Temozolomide improves survival times in vivo. To examine whether combined treatment impacted on survival of tumor-bearing animals in vivo, we implanted viable RN1 cells intracranially into immunocompromised Balb/c mice. Two doses of ibudilast were chosen: 5mg/kg and 20mg/kg delivered by oral gavage while TMZ was administered by i.p. injection (10mg/kg)19. Tumor was confirmed
by humanely euthanizing mice at different time-points during the experiment and checking for tumor with H&E staining. At 43 days post-implantation, large tumors were present and treatment commenced. When all vehicle-treated mice reached their neurological endpoint (median survival 100.5 days), treatment was stopped. The treatment of tumor-bearing mice with ibudilast only resulted in inferior median survival times compared to the vehicle-treated mice (89 days and 97.5 days respectively) (Fig. 5A). A survival advantage was observed with mice treated with TMZ alone (median survival: 105.5 days compared to 100.5 days; LogRank p = 0.055).

Combined treatment resulted in significantly longer survival. Mice treated concurrently with ibudilast (5 mg/kg) and TMZ (10 mg/kg) displayed a median survival of 114 days (p = 0.005) while the combination of ibudilast (20 mg/kg) and TMZ (10 mg/kg) resulted in a median survival of 111.5 days (p = 0.014).

All brains were harvested from the mice and processed for IHC and immunofluorescence (Tunel). Figure 6 illustrates representative photomicrographs of the harvested brains after staining for: H&E, MIF, CD74, Ki67 and Tunel. Histologically, the brains harvested from the combination treatments showed less mitotic bodies compared to the controls and other treatment groups. Marked reductions in the expression of MIF and CD74 were observed in all treatment arms (with the exception of TMZ only) compared to the control brains. MIF and CD74 expression

---

**Table 3.** Combination Index (CI) values for ibudilast/TMZ combination treatment. Synergistic (CI < 1), Additive (CI = 1), Antagonistic (CI > 1).

| Cell line | Fa = 0.50 | Fa = 0.75 | Fa = 0.90 |
|-----------|-----------|-----------|-----------|
| RN1       | 0.879     | 0.631     | 0.460     |
| BAH1      | 1.184     | 0.857     | 0.500     |

---

**Figure 3.** Combined TMZ and MIF inhibitor (ibudilast) treatment is synergistic in GBM cell lines. Different fractions of the monotherapy IC_{50} doses of ibudilast and TMZ were combined (red line). Cells were treated for 7 days and the cell fraction inhibited was determined with the CellTiter 96® Aqueous Assay. (A) RN1 MGMT unmethylated patient derived cells and (B) BAH1 MGMT methylated patient derived cells. (C,D) Isobolograms were generated using CompuSyn 1.0 software. Using this method, the dose–effect data of the individual drugs measured above were used to determine the expected combination and then statistically compared to the actual combination effect measured to determine whether there was synergism, additivity, or anti-additive interactions. These results are expressed in an isobologram that graphs the effective doses of inhibition at 50% (Fa = 0.5), 75% (Fa = 0.75), and 90% (Fa = 0.9) for the individual drugs as x- and y-intercept values. Synergism is demonstrated in all cell lines by the dose pair plotting as a point below their respective Fa isobole or line. Data depicted are the mean ± SEM from 3 replicate experiments.
was not detected in any of the mice brains harvested from the combination arms. The proliferation index marker, Ki67 was used to determine tumor activity. Ki67 is a nuclear stain and was detected in approximately 10–20% of the brain sections harvested from control mice, TMZ only treated mice and the two ibudilast only treatments. In contrast, Ki67 was detectable in less than 5% of tumor cells in the brains excised from combination-treated mice. Tunel staining of the vehicle-treated mice tumors revealed very low levels of apoptosis (<5%). Concurrent treatment of mice with ibudilast (both concentrations) and TMZ resulted in a 30% increase in Tunel positive cells, indicating active apoptosis in the treated mice tumors.

Discussion

Our findings have significant clinical implications for people with GBM. First, we found patients who relapsed after TMZ treatment had high levels of MIF expression. Secondly, ibudilast, a MIF-specific inhibitor sensitized cells and tumors to TMZ treatment. Since clinical trials involving ibudilast have shown no adverse side effects and the drug readily penetrates the blood brain barrier, treatment of people with glioma with this combination is clinically achievable.

MIF expression has been previously associated with poor prognosis and early tumor recurrence in GBM14–16. The evaluation of a series of bioinformatics databases demonstrated significantly elevated levels of MIF in GBM compared with nontumor tissue and high levels of MIF correlated with poorer survival20. Binding of MIF to the extracellular domain of the non-polymorphic type II integral membrane protein CD74 is necessary as an initial step for the MIF signaling cascade21. There are two major distinct MIF-CD74 interactions; (1) Binding of MIF to

---

**Figure 4.** Combined ibudilast and TMZ treatment results in cell cycle arrest and induces apoptosis in GBM cell lines. RN1 cells were treated *in vitro* for 7-days with ibudilast (195 μM), TMZ (110 μM) or combined treatments. (A) Cell cycle analysis in GBM cell lines treated with vehicle, ibudilast, TMZ or the combination. Data depicted are the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way ANOVA comparing the cells in G0/G1 between treatment groups. Three replicate experiments were conducted. (B) RN1 cell lines were treated with vehicle, ibudilast, TMZ or the combination for 7-days and analyzed using flow cytometry for Annexin V positive, propidium iodide (PI) negative cells. Data depicted are the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way ANOVA. Three replicate experiments were conducted. (C) Representative western blots depicting changes in protein expression in RN1 cells following 7-day treatment with vehicle, ibudilast, TMZ or the combination. Lysates were made and probed with the indicated antibodies.

---

**Figure 5.** MIF inhibition in combination with ibudilast and TMZ treatment results in longer survival *in vivo*. Survival of RN1 PDX model. Tumor-bearing mice were treated with indicated drug combinations with the following doses: Ibudilast (5 mg/kg); Ibudilast (20 mg/kg); TMZ (10 mg/kg); Ibudilast (5 mg/kg) + TMZ (10 mg/kg) and Ibudilast (20 mg/kg) + TMZ (10 mg/kg). There were n = 8 mice in all groups. All treatments ceased by day 100. Survival data is displayed by the Kaplan-Meier curve. LogRank: p = 0.012. Tumors were harvested from all mice in the treatment groups and fixed in formalin for paraffin embedding and sectioning.
CD74 can induce the recruitment of CD44 to the complex, which then activates non-receptor tyrosine kinases, leading ultimately to extracellular signal-regulated kinase phosphorylation and enhanced tumor growth in an autocrine manner or (2) MIF-CD74 complexes with the cysteine-X-cysteine (CXC) chemokine receptors CXCR2 on myeloid cells and CXCR4 on T cells thus influencing the M1/M2 polarization in intra-tumoral immune cells.

MIF exerts multimodal functions in GBM including pro-proliferative, pro-migratory, pro-angiogenic as well as immune-evasive properties\(^{14,15,22}\). In two independent studies, brain tumor initiating cells (BTIC) or glioma stem cells (GSC) were shown to express high levels of MIF\(^{20,23}\). In addition, heightened CD74 expression in GBM cell lines has been implicated in mediating resistance against TMZ in GBM\(^{24}\). Using short hairpin RNA to inhibit CD74 in U87 cells, sensitivity to TMZ treatment was increased\(^{24}\).

Ibudilast (MN166) is an anti-inflammatory drug and an allosteric inhibitor of MIF\(^{17}\), and is approved for clinical use in bronchial asthma and cerebrovascular disorders in Japan. We found that ibudilast alone modestly inhibited cell proliferation in a panel of patient-derived cell lines, however acted synergistically when combined with TMZ resulting in high levels of apoptosis. Based on our analysis of protein lysates collected post-treatment, ibudilast and TMZ not only blocked the interaction between MIF and CD74 but also appeared to degrade the expression levels of these proteins.

Numerous studies have shown that impeding MIF expression levels with antibodies or short interfering RNAs lead to significantly reduced tumor formation in vivo\(^{14,16,20}\). We waited until the tumor was grown to a substantial size before commencing treatment in contrast to investigations using siRNA or shRNA to block MIF expression\(^{20}\). The combination of ibudilast with TMZ resulted in significantly extended survival times. We reported no adverse effects from the combination treatment.

The precise mechanism(s) of how ibudilast works synergistically with TMZ to reduce tumor size and extend survival in mice is not fully clear. MIF inhibition has also been shown to sensitize osteosarcoma cells to cisplatin and doxorubicin\(^{25}\). High levels of MIF have been shown to be involved in immune evasion\(^{15,16,26,27}\). MIF transmits signals to the brain parenchyma and in particular to microglial cells\(^{28}\). Interruption of this glioma-microglia interaction through an antibody-neutralizing approach or small interfering RNA (siRNA)-mediated inhibition of MIF prolonged the survival time in glioma-implanted mice by reinstating the microglial pro-inflammatory M1 function\(^{28}\). MIF has also been suggested to act indirectly as a promoter of GBM progression, via suppression of immunological rejection by activating and protecting the negative regulators, myeloid-derived suppressor cells (MDSCs), within the tumor microenvironment\(^{29}\). In another cancer model, treatment of rhabdomyosarcoma cells with cytotoxic drugs actually increased secretory levels of MIF, leading to immune escape\(^{27}\). Hence, targeting MIF may contribute to restoration of immune sensitivity\(^{27}\). Moreover, our findings hold important clinical application. An early phase clinical trial of ibudilast in combination with TMZ for patients with recurrent GBM is underway.

Figure 6. Immunohistochemistry and immunofluorescence analysis of excised mouse brain derived from the in vivo experiment. Brains from the treated mice (n = 8 per treatment group) were harvested at the time of euthanasia. Sections (4 μm) were cut and mounted on ultrafrost slides. H&E, MIF, CD74 and Ki67 proteins were assessed with IHC while Tunel positivity was assessed with immunofluorescence (IF). Representative photomicrographs are presented from each treatment group (i–iv H&E; vii–xii MIF; xiii–xviii CD74; xix–xxiv Ki67 and xxv–xxx Tunel). All images were taken at a magnification of x20 and the error bars represent 100 μm.
Materials and Methods

Ethics statement. Human specimens and clinical data were collected with approval of the relevant Human Research Ethics Committee (HREC) and all patients provided written informed consent. All animal experiments were approved by the University of New South Wales Animal Care and Ethics Committee (ACEC). All methods were performed in accordance with the relevant guidelines and regulations.

Clinical Specimens and Patient-Derived Cell lines. Fresh frozen tumor specimens (n = 36) and formalin-fixed paraffin embedded (FFPE) tumor specimens (n = 168) of human GBM were obtained from the Kolling Institute Tumour Bank and the Australian Genomics and Clinical Outcomes of Glioma (AGOG) biobanks. Clinical data is summarized in Tables 1 and 2. The patient-derived GBM cell lines, RN1 and BAH1 were provided by Dr Bryan Day (QMIR Berghofer) and grown in neurobasal serum-free media as described previously. All patient-derived cell lines used in this study were authenticated by short tandem repeat (STR) analysis. Cell lines were used within 10 passages and have been verified to be negative for mycoplasma contamination. All clinical specimens and cell lines were tested for MGMT methylation using pyrosequencing as described previously.

Preparation of protein sample and protein chips for SELDI-TOF MS. Proteins extracted from fresh frozen GBM surgical specimens (n = 36) were analyzed by TOF MS on SELDI protein chip arrays (Bio-Rad) as previously described. All mass spectra were obtained in the m/z range of 2,500–70,000 with the ProteinChip SELDI system Enterprise Edition (Bio-Rad). Mean values from duplicate spectra for each sample were used in all subsequent analyses. The m/z for each peak was determined using external calibration with protein standards as previously described. After pre-processing of data, intensities of each peak in the group were averaged for each sample. Differences between samples and the two groups were determined by Expression Difference Mapping (EDM) using Data manager Software 4 (Enterprise Edition Bio-Rad). For each significantly differentially expressed protein, receiver operating characteristic (ROC) curves were constructed to obtain area under curve (AUC) values (SPSS Software Version 18.0). AUC values which range from 0.5 (no discrimination) to 1.0 (absolute prediction) were compared using the Hanley & McNeil method to evaluate discriminatory power of proteins and the significance of ROC curves. Backward stepwise binary logistic regression (BLR) procedure was applied to compute contribution of individual markers to the separation of the two test groups and also to estimate the complimentary performance of multiple biomarkers. Protein extracts were further purified using the Mustang S cation-exchange AcroPrep 96 Filter Plate (Pall Corporation) and fractionated by Reverse Phase High Performance Liquid Chromatography (RP-HPLC) (Model 510, Waters Corporation) to obtain purified subfrations containing proteins of interest. For protein identification, samples were sent to the Bio-analytical Mass Spectrometry Facility (BMSF), University of New South Wales, Sydney, Australia.

Immunohistochemistry (IHC) and Scoring. Immunohistochemistry (IHC) was performed with a well-characterized MIF antibody on formalin-fixed paraffin-embedded GBM specimens from 168 patients who had undergone craniotomy. Sections (4 μM) were deparaffinised and dehydrated. Human breast cancer tissue was used as a positive control. Sections were treated with peroxidase block reagent (Bond polymer refine detection kit, Leica) to block endogenous peroxide activity. The sections were immunostained with MIF (MAB289, R&D Systems; 1:8000) on a Bond X automated immunostainer (Leica) for 30 minutes. Immunostaining was developed with DAB-chromagen for 10 minutes and counterstained with haematoxylin to allow nuclei visualization. Stained sections were scored by two independent pathologists. Cytoplasmic staining was scored as intensity with 0 = no staining; 1 = weak staining; 2 = moderate staining and 3 = strong staining.

Drug compounds. MN-166 (ibudilast) was kindly supplied by MediciNova Inc. Temozolomide (TMZ) was purchased from Sigma Aldrich. All drugs for in vitro and in vivo use were reconstituted in DMSO at 10 mM. Doses used are detailed in Figure legends.

Combination treatment synergy quantitation. Drug combinations studies were performed according to the Chou-Talalay method of synergy quantitation. Patient derived cell lines were treated in vitro for 7-days with the combination of ibudilast and TMZ over a range of concentrations held at a fixed ratio based on the IC50 (drug concentration required for 50% growth inhibition) of each drug specific for each cell line. CompuSyn 1.0 performs multiple drug dose-effect calculations using the Median Effects methods described by Chou and Talalay and was used to determine the combination index (CI) which offers quantitative definition for additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) of drug combinations.

Flow cytometry analysis. Cells were plated in 24-well plates and treated the following day with the indicated agents. After treatment with drugs, cells were harvested at 7-days and fixed in cold 70% v/v ethanol overnight and stored at −20 °C. Fixed cells were washed with phosphate-buffered saline (PBS) and stained in the dark with a solution containing a final concentration of propidium iodide (PI) (50 μg/mL) (Sigma), Triton X-100 (0.25%) and RNase (1 mg/mL) for 1 hour at room temp (0.25%). DNA content was analyzed using a BD FACSCanto II flow cytometer (BD Biosciences) and data analysis was performed using FlowJo v.10 (TreeStar Inc).

Apoptosis was quantified as a percentage using an Annexin V-fluorescein isothiocyanate (FITC)/PI apoptosis detection kit (BD) according to the manufacturer’s instructions. Cells in the logarithmic growth phase were treated with the various drugs and combination and cells were harvested using Accutase (Sigma-Aldrich), and Annexin-V-FITC/PI labeling was performed according to the manufacturers’ instructions. The stained cells were analyzed using a BD FACSCanto II flow cytometer (BD Biosciences). The number of viable (annexin V−/PI−), apoptotic (annexin V+/PI−), and necrotic (annexin V+/PI+) cells were calculated with FlowJo v.10 (TreeStar Inc).
Western blot analysis. Cells were plated in 6-well plates and treated the following day as indicated. Cells were lysed by incubation in RIPA lysis buffer supplemented with PMSF and protease inhibitors. Protein concentrations were normalized using a BCA protein assay (Pierce Biotechnology). Proteins were denatured using Laemmli denaturing buffer (Bio-Rad Laboratories) supplemented with β-mercaptoethanol and separated on a 12% polyacrylamide SDS-PAGE gel. Proteins were transferred to a PVDF membrane and immunoblotted using the antibodies described. Membranes were developed using Clarity™ Western ECL Substrate (Bio-Rad Chemiluminescence system (BioRAD #170-506). The following primary antibodies were used at a dilution of 1:1000: MIF antibody (Abcam #ab7207), CD74 antibody [LN2] (Abcam AB9514), p44/p42 MAPK (Erk1/2) (LS4F12) Mouse mAb (Cell Signaling #4696S), p-p44/42, AKT, Cleaved PARP (Asp214) Antibody (Cell Signaling), Anti-CXCR2 antibody (ABCAM #ab14935), Anti-Src antibody [EPR5496] (ABCAM #ab109381). In addition, the following primary antibodies were also used at a dilution of 1:2000: CD44 (anti CD44 Ab from Abcam #ab51037), p-AKT (Cell signaling #9271S), CXCR4 (Cell signaling). Secondary antibodies were purchased from BioRad Immun-Star Goat Anti-Rabbit (GAR)-HRP Conjugate (BioRad) or Polyclonal Goat Anti-Mouse Immunoglobulins HRP. Beta-Actin (Dako) was used as a housekeeping gene on each membrane to assess the integrity and quantity of the extracts.

In vivo studies. Eight week old female Balb/c nude mice (nu/nu) were used for RN1 patient-derived xenograft model. Approximately 2 × 10^6 RN1 cells were intracranially implanted into the mice brains (1.0 mm, 1.5 mm lateral from the bregma and 3.0 mm deep). Tumor burden was assessed by humanely euthanizing mice daily between 40–50 days. Tumor was embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E). Treatment commenced at 43 days after implantation. Mice (n = 8) were randomized to the treatment groups. Ibudilast was administered by oral gavage and was given daily throughout the duration of the experiment (until all control mice had died). TMZ was administered by intraperitoneal (i.p.) injection at a schedule of 5 days per week (2 weeks on, 2 weeks off) for the duration of the experiment (until all control mice had died). Mice were euthanized if the animals displayed neurological health indicators that met the institutional criteria for sacrifice. Animal experiments were approved by University of New South Wales Animal Care and Ethics Committee (16/86A) and conducted in accordance with the National Health and Medical Research Council Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.

Statistical analyses. One-way analysis of variance (ANOVA) with Tukey’s multiple comparison test was used to compare between treatment groups. Survival differences between groups were determined using Kaplan–Meier log rank analysis. Statistical analyses (not including proteomics analysis) were performed using Prism 7 (GraphPad). A two-tailed p < 0.05 was considered statistically significant. All data are expressed as mean ± SEM.

References
1. Welfare, A. L. O. H. A. Australian Cancer Incidence and Mortality (ACIM) books: Brain Cancer. (AIHW Canberra, 2017).
2. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987–996 (2005).
3. Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B. & Herman, J. G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59, 793–797 (1999).
4. Felsberg, J. et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 129, 659–670 (2011).
5. Esteller, M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 36, 2294–2300 (2000).
6. Esteller, M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21, 5427–5440 (2002).
7. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997–1003 (2005).
8. Reifenberger, G. et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 111, 216–221 (2004).
9. Stummer, W. et al. Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. J Neurooncol (2010).
10. Hoppold, C. & Weller, M. New insights into acquired temozolomide resistance in glioblastoma? Brain 138, 3468–3470 (2015).
11. Hermisson, M. et al. O6-ethylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96, 766–778 (2006).
12. Strielkeberger, J., Dieter, L., Bueki, R., Fietkau, R. & Putz, E. F. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine. Clin Transl Oncol (2017).
13. Zhu, D. et al. Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting miR-107. Cancer Med 6, 452–462 (2017).
14. Baron, N. et al. Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells. J Neurosci Res 89, 711–717 (2011).
15. Mittelbronn, M. et al. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathol 122, 353–365 (2011).
16. Polajeva, J. et al. Glioma-derived macrophage migration inhibitory factor (MIF) promotes mast cell recruitment in a STAT3-dependent manner. Mol Oncol 8, 50–58 (2014).
17. Cho, Y. et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA 107, 11313–11318 (2010).
18. Sanftner, L. M. et al. Cross-species comparisons of the pharmacokinetics of ibudilast. Xenobiotica 39, 964–977 (2009).
19. Dinca, E. B. et al. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res 68, 10034–10039 (2008).
20. Otros, B. et al. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion. Stem Cells 34, 2026–2039 (2016).
21. Lan, H. Y. Role of macrophage migration inhibition factor in kidney disease. Nephron Exp Nephrol 109, e79–83 (2008).
22. Bacher, M. et al. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol 162, 11–17 (2003).
23. Fukaya, R. et al. MIF Maintains the Tumorigenic Capacity of Brain Tumor-Initiating Cells by Directly Inhibiting p53. *Cancer Res* **76**, 2813–2823 (2016).
24. Kitange, G. J. et al. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. *J Neurooncol* **100**, 177–186 (2010).
25. Wang, C. et al. Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the RAS/MAPK pathway. *Cancer Lett* **403**, 271–279 (2017).
26. Hussain, F. et al. Human anti-macrophage migration inhibitory factor antibodies inhibit growth of human prostate cancer cells in vitro and in vivo. *Mol Cancer Ther* **12**, 1223–1234 (2013).
27. Johler, S. M., Fuchs, J., Seitz, G. & Armeanu-Ebinger, S. Macrophage migration inhibitory factor (MIF) is induced by cytotoxic drugs and is involved in immune escape and migration in childhood rhabdomyosarcoma. *Cancer Immunol Immunother* **65**, 1465–1476 (2016).
28. Ghoochani, A. et al. MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis. *Oncogene* **35**, 6246–6261 (2016).
29. Rahman, M. et al. Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines. *Anat Cell Biol* **48**, 23–35 (2015).
30. Jue, T. R. et al. Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma. *J Transl Med* **15**, 61 (2017).
31. McDonald, K. L. et al. The T genotype of the MGMT C > T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. *Eur J Cancer* **49**, 360–368 (2013).
32. Chung, L. et al. Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. *Breast Cancer Res* **16**, R63 (2014).
33. Hanley, J. A. & Mcneil, B. J. The Meaning and Use of the Area under a Receiver Operating Characteristic (Roc) Curve. *Radiology* **143**, 29–36 (1982).
34. Hanley, J. A. & Mcneil, B. J. A Method of Comparing the Areas under Receiver Operating Characteristic Curves Derived from the Same Cases. *Radiology* **148**, 839–843 (1983).
35. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmaco
col Rev* **58**, 621–681 (2006).
36. Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv Enzyme Regul* **22**, 27–55 (1984).
37. Reagan-Shaw, S., Ñihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. *FASEB J* **22**, 659–661 (2008).

**Acknowledgements**

The authors would like to acknowledge funding contributions from the Cure Brain Cancer Foundation and The Olle Fund for Brain Cancer Research. We would also like to thank Dr Bryan Day (QIMR Berghofer) for the patient derived cell lines, RN1 and BAH1.

**Author Contributions**

W.H., H.S.N., A.Z., L.C. and K.L.M. performed all experimental work. K.M., M.K., W.H., R.B. and K.L.M. contributed to statistical analyses and manuscript writing.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-019-39427-4.

**Competing Interests:** W.H., H.S.N., A.Z., M.K., A.N., L.C., R.B. and K.L.M. have no competing interests to declare. K.M. is an employee of MediciNova.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019